Ovarian cancer vaccine - Life Research Technologies
Alternative Names: Autologous TERT-mRNA survivin peptide-loaded dendritic cell vaccine - CELLMED; Procure; TERT-mRNA and survivin-peptide double loaded dendritic cellsLatest Information Update: 30 Oct 2021
At a glance
- Originator LIFE RESEARCH Technologies
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action CD4-positive T-lymphocyte stimulants; CD8 positive T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Ovarian cancer
Most Recent Events
- 11 Mar 2017 Discontinued - Phase-I/II for Ovarian cancer (Late-stage disease, Adjuvant therapy) in Austria and Hungary (Intradermal)
- 11 Apr 2016 Life Research Technologies plans a phase IIb trial for Ovarian cancer (Recurrent, Late-stage disease) in Germany (CELLMED website)
- 30 Sep 2010 Phase-I/II clinical trials in Ovarian cancer in Austria (Intradermal)